Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report

References

• Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428–5. doi: 10.1016/S0140-6736(21)00153-7.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. First-line chemotherapy in advanced biliary tract cancer Ten years after the ABC-02 trial: “and yet It Moves!”. Cancer Treat Res Commun. 2021;27:100335. doi: 10.1016/j.ctarc.2021.100335.
   PubMedGoogle Scholar
• Zhou J, Sun Y, Zhang W, Yuan J, Peng Z, Wang W, Gong J, Yang L, Cao Y, Zhao H, et al. Phase b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology. 2023;77(1):65–76. doi: 10.1002/hep.32548.
   PubMed Web of Science ®Google Scholar
• Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges J-P, Bellera C, Adenis A, Korakis I, Poureau P-G, et al. Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer. 2022;162:161–9. doi: 10.1016/j.ejca.2021.11.012.
   PubMed Web of Science ®Google Scholar
• Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, Bai Y, Bian J, Zhang L, Yang X, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr. 2020;9(4):414–24. doi: 10.21037/hbsn-20-338.
   PubMed Web of Science ®Google Scholar
• Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JL, Palena C, Schlom J. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. J Immunother Cancer. 2020;8:e000433. doi: 10.1136/jitc-2019-000433.
   PubMed Web of Science ®Google Scholar
• Xia L, Peng J, Lou G, Pan M, Zhou Q, Hu W, Shi H, Wang L, Gao Y, Zhu J, et al. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. J Immunother Cancer. 2022;10(1):2022. doi: 10.1136/jitc-2021-003831.
   Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690–701. doi: 10.1016/S1470-2045(21)00027-9.
   PubMed Web of Science ®Google Scholar
• Grossman JE, Vasudevan D, Joyce CE, Hildago M. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene. 2021;40:1393–5. doi: 10.1038/s41388-020-01611-6.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. doi: 10.1016/S0140-6736(16)32517-X.
   PubMed Web of Science ®Google Scholar
• Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, Joshua AM, Hodi FS, Gangadhar TC, Hersey P, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;32:. doi: 10.1200/jco.2014.32.15_suppl.3005.
   Web of Science ®Google Scholar
• Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119(2):153–9. doi: 10.1038/s41416-018-0131-9.
   PubMed Web of Science ®Google Scholar
• Naumann RW, Hollebecque A, Meyer T, Devlin M-J, Oaknin A, Kerger J, López-Picazo JM, Machiels J-P, Delord J-P, Evans TRJ, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019;37(31):2825–34. doi: 10.1200/JCO.19.00739.
   PubMed Web of Science ®Google Scholar
• Dos Santos Fernandes G, da Motta Girardi D, Dib Batista Bugiato Faria L, Giacomini Bernardes JP, de Almeida Coudry R. Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection? J Immunother Cancer. 2017;5:84. doi: 10.1186/s40425-017-0291-9.
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023;72(6):1365–79. doi: 10.1007/s00262-022-03349-4.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Sancho E, Batlle E. Overcoming TGFβ-mediated immune evasion in cancer. Nat Rev Cancer. 2022;22(1):25–44. doi: 10.1038/s41568-021-00413-6.
   PubMed Web of Science ®Google Scholar
• Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, Demetriou P, Pierides C, Polydorou C, Stylianou A, et al. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics. 2020;10(4):1910–22. doi: 10.7150/thno.36936.
   PubMed Web of Science ®Google Scholar
• Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A, Yeung T-L, Hasheminasab S-M, Jenkins MH, Meister S, et al. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021;39(10):1388–403.e10. doi: 10.1016/j.ccell.2021.08.008.
   PubMed Web of Science ®Google Scholar
• Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6:74. doi: 10.1186/s40425-018-0383-1.
   PubMed Web of Science ®Google Scholar
• Salati M, Caputo F, Baldessari C, Carotenuto, P, Messina, M, Caramaschi, S, Dominici, M, Bonetti, L.R. The evolving iole of FGFR2 inhibitors in intrahepatic Cholangiocarcinoma: from molecular biology to clinical targeting. Cancer Manag Res. 2021;13:7747–57. doi: 10.2147/CMAR.S330710.
   PubMed Web of Science ®Google Scholar
• Xie C, Zhou J, Guo Z, Diao X, Gao Z, Zhong D, Jiang H, Zhang L, Chen X. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013;168:1687–706. doi: 10.1111/bph.12047.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zuo C, Liu L, Hu Y, Yang B, Qiu S, Li Y, Cao D, Ju Z, Ge J, et al. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer. J Hepatol. 2021;75(5):1128–41. doi: 10.1016/j.jhep.2021.06.023.
   PubMed Web of Science ®Google Scholar